The Drug Discovery report series
The Drug Discovery Series from Business Insights tackles the issues impeding innovation for R&D executives and assesses the cutting edge approaches and technologies companies can use to overcome the productivity gap.
Preclinical Models: Innovative solutions to accelerate drug discovery and development
This report explores novel preclinical models that show promise to expedite and improve the target validation and lead optimization timeline and discusses the various advantages and disadvantages of ADMET screening technologies to provide insight on which models or systems may enhance the R&D function of pharmaceutical and biotechnology organisations.
Table of contents | More information
Nanotechnology in Healthcare: Market outlook for applications, tools and materials, and 40 company profiles
The advent of healthcare nanotechnology has had a vast impact in the fields of drug delivery and diagnostics.
Table of contents | More information
DNA Sequencing In Drug Discovery: Market outlook for applications, tools and services, and 40 company profiles
The advent of DNA sequencing technology has had a vast impact on the field of drug development. It has played a key role in the success of the Human Genome Project which has made it an essential tool for genetic analysis.
Table of contents | More information
Innovations In Epigenetics: Advances in Technologies, Diagnostics & Therapeutics
The study of epigenetics - changes in gene expression that occur without a change in a cell’s DNA code – is becoming increasingly important as scientists explore how internal and external factors trigger cellular dysfunction and influence disease progression.
Table of contents | More information
Advances in the Stem Cell Industry: The future impact of innovation, and an evaluation of the commercial landscape
An important milestone in the development of stem cell technology occurred in 2007, when researchers induced human cells into a stem cell state using defined genetic factors. These cells are now known as induced pluripotent stem (IPS) cells; they offer an alternative to using embryonic stem cells. This report takes the implications of IPS cells and other developments into account.
Table of contents | More information
The Global Bioinformatics Market: Market size, forecasts and company profiles
This report segments the bioinformatics market on a number of levels: tools, services, content/database, applications and region, providing market forecasts to 2014.
Table of contents | More information
Accelerating Lead Generation: Emerging technologies and strategies
This report assesses the potential of new and emerging technologies for improving the quality of drug candidates entering clinical research, and reviews the benefits associated with different approaches to lead generation, including high throughput screening, fragment based drug discovery and virtual screening.
Table of contents | Brochure | More information
Innovations in Protein Kinase Therapies
This report identifies areas of innovation and opportunity for kinase targeting drugs in cancer and examines the non-cancer applications of kinase drugs across inflammatory/autoimmune diseases, restenosis, diabetes, and other disorders.
Table of contents | More information
Early Stage Drug Safety Strategies and Risk Management
This report evaluates the latest innovative predictive technologies being introduced into pre-clinical and early clinical development phases and also explores the potential cost savings and challenges associated with their implementation.
Table of contents | Brochure | More information
R&D Cost Cutting: Managing cost containment and safeguarding productivity
This report analyses changes to drug development imperatives caused by increased financial restrictions, and uses detailed case studies to assess leading cost reducing approaches such as internal refocusing, outsourcing/offshoring and drug development alliances.
Table of contents | Brochure | More information
The Future of Biobanks
This report explores the applications of biobanks and provides examples of how large sets of high-quality biosamples are creating new ways to diagnose, prevent and treat diseases. The activities of over 180 US biobanks are assessed to illustrate how the scale and scope of biobanking is changing. This report also evaluates the limitations of biobanks, in addition to reviewing the unique legal, regulatory and ethical issues that surround this new frontier of biomolecular research.
Table of contents | Brochure | More information
The Future of RNAi Therapeutics: Drug Pipelines and Prospects
‘The Future of RNAi Therapeutics: Drug pipelines and prospects’ is a new report published by Business Insights that provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas including infectious diseases, cancer, inflammation/immune dysfunction, CNS disorders and cardiology/metabolism.
Table of contents | Brochure | More information
Innovative Strategies and Models for R&D Success
'Many pharma companies are currently engaged in wide-scale R&D restructuring, adopting a biotechnological approach to drug development by establishing disease-focused R&D units, R&D spin-offs, strategic partnerships and joint ventures. This trend has been reinforced by the emergence of public/private partnerships, co-operatives and open-source research initiatives that have encouraged companies to target previously neglected disease areas such as biotherapeutics and vaccines.
Table of contents | Brochure | More information
The Emerging Role of Postmarketing Clinical Research
'The Emerging Role of Postmarketing Clinical Research’ is a new report published by Business Insights that uses detailed case studies and market scenarios to examine the latest issues surrounding phase IV trial applications. The potential to leverage competitive advantage with postmarketing research is assessed by measuring the implications for formulary access, product marketing, indication expansion and reimbursement coverage.
Table of contents | Brochure | More information
Innovative Clinical Trial Design and Management
‘Innovative Clinical Trial Design and Management’ is a new report published by Business Insights that explores the major types of adaptive design and their role in dose-finding. The report investigates seamless Phase 2/3 trials and adaptive trials in pharmacogenomics, assesses the logistical implications of adaptive trial implementations and reviews the current regulatory standpoints of the FDA and EMEA.
Table of contents | Brochure | More information
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
In recent years, there have been concerted efforts to enhance the precision of disease diagnosis and monitoring as the hetrogeneity of conditions becomes increasingly understood. Targeting broad patient populations in a ‘one-pill-fits-all’ approach has begun to attract criticism, with the average efficacy of such drugs being estimated at 50% or less.
Table of contents | Brochure | More information
Innovations in Bioinformatics: Emerging tools for drug discovery and development
R&D laboratories are co-ordinating the analysis of increasingly prohibitive volumes of disparate biological data, much of which is comprised of gene and protein sequences. Companies are now integrating bioinformatics-enabled data management to tackle this deluge and improve productivity within their R&D programmes by identifying new drug targets, biomarkers of drug efficacy and toxicity, and diagnostic biomarkers.
Table of contents | Brochure | More information
Nanotechnology: Revolutionizing R&D to develop smarter therapeutics and diagnostics
Nanotechnologies have already attracted over $3bn of global government funding as part of efforts to enhance a range of disciplines including pharmaceuticals, drug delivery and healthcare monitoring. Advances in nanomaterials, nanostructures and nanosystems are expected to drive the value of the global nanotehnology market to over a trillion dollars by 2015
Table of contents | Brochure | More information
Translational Medicine in Biopharmaceutical R&D
As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency of drug research...
Table of contents | Brochure | More information
Drug Development Opportunities in China
Identify the factors attracting global drug developers to China, assess future growth opportunities within the domestic pharma and biotech markets and deploy outsourced R&D more effectively with this new report...
Table of contents | Brochure | More information
Immunomodulators: Therapeutic Needs, Pipelines & Prospects
The strategies and technologies used in immunomodulation are analysed and the major clinical applications of immunomodulators are reviewed to identify the leading drug classes and most promising agents currently in development.
Table of contents | Brochure | More information
Outlook for RNAi, 2007: siRNA and miRNA in biology, diagnostics and therapeutics
The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials.
Table of contents | Brochure | More information
Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity
This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them,
Table of contents | Brochure | More information
Next Generation Protein Engineering and Drug Design
This report provides a detailed insight into the current market for engineered proteins and peptides, and explores the key factors of commercial success for the development of next generation products.
Table of contents | Brochure | More information
Biopartnering Strategies: Maximizing returns from biotechnology deal-making
Use this report to implement the optimal biopartnering strategy for your company’s needs as it progresses through the ‘pioneer’, ‘growth’ and ‘consolidation’ stages.
Table of contents | Brochure | More information
Winning R&D Productivity Strategies
Use this report to identify key areas of growth, effective strategies and innovative technologies to improve lead generation.
Table of contents | Brochure | More information
The Future of Metabolomics: Building competitive advantage in drug discovery...
Explore potential cost savings, and recognize lucrative partnering opportunities in this fast moving field with this report.
Table of contents | Brochure | More information
Commercial Opportunities from Biomarkers
This report will ensure that you are able streamline your R&D process and identify potential cost savings throughout drug discovery and development.
Table of contents | Brochure | More information
Opportunities in Stem Cell Research
Identify potential alliance partners and plan a long-term growth strategy to secure your leading position in this market. with this report.
Table of contents | Brochure | More information
Predictive ADME and Toxicology Strategies
This report focuses on how novel predictive toxicology and ADME methods can provide a better return on investment and reduce drug attrition rates in clinical trials.
Table of contents | Brochure | More information
The Emerging Drug Targets Outlook
Drug targets are generally proteins. Nucleic acids are possible drug targets, and approaches such as RNA interference (RNAi) may indeed have advantages over proteins, but they have not so far been developed extensively.
Table of contents | More information
The Future of Systems Biology: Emerging technologies and their impact on drug discovery...
This report will help you to maximize the cost and time saving benefits offered by biological systems in these areas to secure your frontline position in the marketplace.
Table of contents | Brochure | More information
The Future of Array Technologies
This report reviews recent M&A activity in the array market, enabling you to identify synergies and competitive advantages that can be achieved through collaboration.
Table of contents | Brochure | More information
Lead Optimization Strategies
This report details important service providers for lead optimization outsourcing used by the pharmaceutical industry, in order to address the rising costs of drug development and improve drug attrition rates.
Table of contents | Brochure | More information
The Outlook For RNAi: Accelerating drug discovery....
This report analyzes future trends of RNAi and provides detailed insight into the most effective use of this novel technology in the drug discovery process .
Table of contents | Brochure | More information
Emerging Drug Discovery Technologies
Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi, is a new report which provides an in-depth analysis of three technological innovations that are being heralded to revolutionize the drug discovery process by rapidly expediting drug discovery research.
Table of contents | Brochure | More information
|
